NCT00409201

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (planned)
• Sponsor: Abarbanel Mental Health Center · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

Detailed description

all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as well as blood tests, ecg and weight. they will then be tested using a computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given either a two week dose of placebo or treatment (2 mg \* 2 daily for first week, then 4 mg. day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. \* 2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is concluded at 6 weeks, following a readministration of tests. physical examination is also administered at the conclusion.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	reboxetine adjuvant therapy

Timeline

• Start date: 2006-03-01
• Completion: 2006-11-01
• First posted: 2006-12-08
• Last updated: 2006-12-08

Locations

2 sites across 1 country: Israel